These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38261309)

  • 1. Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors.
    Li Pomi F; Vaccaro F; Borgia F; Irrera N; Vaccaro M
    Ital J Dermatol Venerol; 2024 Apr; 159(2):212-214. PubMed ID: 38261309
    [No Abstract]   [Full Text] [Related]  

  • 2. Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report.
    Xie L; Feng Y; Sun J
    J Clin Pharm Ther; 2022 Feb; 47(2):248-250. PubMed ID: 34240438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
    Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
    Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
    Kanaji N; Ichihara E; Tanaka T; Ninomiya T; Kozuki T; Ishikawa N; Nishii K; Shoda H; Yamaguchi K; Kawakado K; Toyoda Y; Inoue M; Miyatake N; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kojima K; Kadowaki N
    Lung; 2024 Feb; 202(1):63-72. PubMed ID: 38265672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report of toxic epidermal necrolysis associated with AZD-9291.
    Wang J; Cheng X; Lu Y; Zhou B
    Drug Des Devel Ther; 2018; 12():2163-2167. PubMed ID: 30034220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
    N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
    Shin E; Lim DH; Han J; Nam DH; Park K; Ahn MJ; Kang WK; Lee J; Ahn JS; Lee SH; Sun JM; Jung HA; Chung TY
    BMC Ophthalmol; 2020 Jan; 20(1):19. PubMed ID: 31918686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Lin G; Liu Y; Li H; Chen S; Guo Y
    Clin Lung Cancer; 2021 Mar; 22(2):e157-e159. PubMed ID: 33158763
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal interstitial lung disease associated with AZD9291.
    Deng SM; Huang JA; Chen YB
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1227-S1229. PubMed ID: 30539877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
    Hayashi H; Yonesaka K; Nakamura A; Fujimoto D; Azuma K; Sakata S; Tachihara M; Ikeda S; Yokoyama T; Hataji O; Yano Y; Hirano K; Daga H; Okada H; Chiba Y; Sakai K; Nishio K; Yamamoto N; Nakagawa K
    Lung Cancer; 2022 Jun; 168():38-45. PubMed ID: 35477147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer.
    Lin YT; Chu CY
    Lung Cancer; 2019 Mar; 129():110-111. PubMed ID: 30612819
    [No Abstract]   [Full Text] [Related]  

  • 14. Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.
    Sato I; Mizuno H; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Ogura Y; Hirose K; Takeda T
    Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32796633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
    Yu Z; Xu F; Zou J
    Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olmutinib-induced palmoplantar keratoderma.
    Chen KL; Cho YT; Yang CW; Sheen YS; Liang CW; Lacouture ME; Chu CY
    Br J Dermatol; 2018 Feb; 178(2):e129-e131. PubMed ID: 28869782
    [No Abstract]   [Full Text] [Related]  

  • 17. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
    Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
    Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
    Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
    Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
    Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
    Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.